While the Medicare GLP-1 Bridge Program has expanded access to certain obesity medications for eligible beneficiaries, not everyone with Medicare will qualify
We offer regular check-ins, educational resources, and access to a network of specialists to ensure you achieve the best possible outcomes
Fewer degranulating mast cells means less histamine release, fewer prostaglandins, fewer leukotrienes, and a dramatically reduced allergic response
Individual variation is substantial, which is why genetic testing and dose personalization matter
Although frequently sold alongside peptides, it is chemically very different
This shortage first reached Australia in 2022, and the Therapeutic Goods Administration (TGA) expects it will last until at least the end of this year